Hua Medicine (the Company, HKG: 2552) announced today that the Company presented the latest research results of dorzagliatin, its global…
Browsing: Hua Medicine
– HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in…
On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai’s Industry and Commerce…
On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong…
Hua Medicine (the Company, HKG: 2552) announced today that the Company has successfully completed a Phase I clinical trial on…
Hua Medicine (the Company, HKG: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism…
The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li,…
Hua Medicine (Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type…
Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for…
Hua Medicine (the “Company”, Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder (“MAH”)…
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its…
Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing…
Hua Medicine (the “Company”, Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. HMM0112 is…
Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 Weeks Dorzagliatin-Driven Portfolio Expands Hua Medicine (the “Company”, Stock Code…
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has…